ClinicalTrials.Veeva

Menu
The trial is taking place at:
G

Gateway Community Service | Jacksonville, FL

Veeva-enabled site

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (MOMs-INO)

T

T. John Winhusen, PhD

Status and phase

Enrolling
Phase 3

Conditions

Neonatal Opiate Withdrawal Syndrome
Opioid-Related Disorders
Pregnancy Related
Drug Abuse
Neonatal Abstinence Syndrome
Substance Abuse
Drug Abuse in Pregnancy
Drug Addiction

Treatments

Drug: Buprenorphine Sublingual Product
Drug: Buprenorphine Injection

Study type

Interventional

Funder types

Other
Industry
NIH

Identifiers

NCT03911739
UG1DA013732 (U.S. NIH Grant/Contract)
2019-0429-3

Details and patient eligibility

About

This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Caretakers of the infants delivered by MOMs participants will be offered the opportunity to enroll in this sub-study, which is designed to evaluate the impact of extended-release buprenorphine (BUP-XR), relative to sublingual buprenorphine (BUP-SL), on infant neurodevelopment. The additional data collected in this sub-study will be combined with data from the main MOMs trial.

Enrollment

200 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The participant must be the caretaker of an infant that was delivered as part of the MOMs trial (Unique protocol ID: 2019-0429-1).

Exclusion criteria

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

BUP-XR
Experimental group
Description:
Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly. The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.).
Treatment:
Drug: Buprenorphine Injection
BUP-SL
Active Comparator group
Description:
Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase. The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.).
Treatment:
Drug: Buprenorphine Sublingual Product

Trial contacts and locations

13

Loading...

Central trial contact

Frankie Kropp, MS; Ben Kropp, MSLS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems